Is it safe for a patient with an autoimmune disease to undergo platelet‑rich plasma (PRP) therapy, and what are the recommendations regarding disease activity, medication use, treatment protocol, and alternative options?

PRP Therapy in Autoimmune Disease: Safety and Recommendations

Autologous PRP therapy is generally safe for patients with autoimmune diseases, with no absolute contraindications based on autoimmune status alone, though specific considerations regarding disease activity, immunosuppression, and infection risk must be addressed. 1, 2

Safety Profile

PRP is fundamentally safe in autoimmune conditions because:

• Autologous/allogeneic sterile PRP preparations are clinically safe according to ISTH consensus guidelines 1
• Case series demonstrate successful PRP use in rheumatoid arthritis patients with inadequate response to conventional therapy, showing sustained improvement for up to 1 year without adverse effects 3
• PRP has been used successfully in autoimmune blistering diseases (mucous membrane pemphigoid) with 100% of patients reporting improvement and no adverse reactions 4

Key Contraindications and Precautions

Based on 2025 GRIIP consensus recommendations 2, PRP should be avoided or delayed in these specific scenarios:

Infectious Considerations

• Active systemic infection - absolute contraindication
• Active local infection at injection site - absolute contraindication
• Immunosuppressive therapy - requires careful risk-benefit assessment due to altered immune response and infection risk
• Recent dental procedures - timing considerations for infection risk

Hematologic Considerations

• Active cytopenia - may affect PRP quality and composition
• Active hemopathy - requires hematology consultation
• Unstabilized hematologic disease - defer until stabilized

Oncologic Considerations

• Active local tumor at injection site - absolute contraindication
• Active cancer - requires oncology clearance
• Cancer in remission - generally acceptable with appropriate timing

Disease Activity Assessment

PRP can be administered regardless of autoimmune disease activity status, as demonstrated in the rheumatoid arthritis case series where patients with persistent inflammation despite ongoing treatments showed improvement 3. However:

• Leukocyte-rich PRP contains inflammatory cytokines that modulate immune responses 5
• The anti-inflammatory effects appear to work through downregulation of inflammatory cytokines and modulation of synovial cell proliferation 3

Medication Interactions

Continue existing immunosuppressive therapy - the rheumatoid arthritis cases showed efficacy "irrespective of past and ongoing treatments" 3. No evidence suggests discontinuation of:

• DMARDs
• Biologics
• Corticosteroids
• Other immunosuppressants

Treatment Protocol Recommendations

Preparation Standards

• Use manual double-spin method 6
• Avoid EDTA anticoagulant (use citrate, ACD, or CPD) 1
• Target platelet concentration: 1.0-1.5 million platelets/μL 6
• Leukocyte-poor PRP preferred for inflammatory conditions 7

Administration Protocol

• Minimum 3-5 sessions 6
• 1 month intervals between sessions 6
• Dose: 5-7 mL PRP (0.05-0.1 mL/cm² for dermatologic applications) 6
• No activation required for most applications 6

Follow-up

• Evaluate after completing initial series
• Maintenance: 1 session every 6 months if beneficial 6

Critical Pitfalls to Avoid

1. Contamination risk - Most common adverse event is postoperative infection due to microbial contamination during preparation or administration 8. Maintain strict sterile technique throughout.

2. Poor standardization - PRP preparations vary widely in content, purity, and biological properties 1. Use validated preparation methods and document platelet concentration, leukocyte content, and activation status.

3. Inadequate patient selection - Screen for active infections, unstabilized hematologic conditions, and local malignancy before proceeding 2

4. Timing with dental procedures - Coordinate timing to minimize infection risk in immunosuppressed patients 2

Alternative Considerations

If PRP is contraindicated or unavailable:

• Hyaluronic acid - though PRP shows superior outcomes in musculoskeletal applications 7
• Corticosteroid injections - though PRP may be considered when these fail 3
• Conventional immunosuppressive optimization - address underlying disease control first

Evidence Quality Note

The ISTH guidelines rate overall PRP evidence as "uncertain" for many applications (median scores 4-6) 1, and most recommendations are Grade D (expert opinion) due to limited high-quality trials 2. However, the safety profile is consistently rated as "appropriate" (median 7.5-8.5) 1, making it a reasonable option when standard therapies fail.